News and Trends 4 Dec 2017 Israeli Biotech Gets $30M Backing for its Immune Modulators for Severe Infections Atox Bio develops immune modulators to save patients with severe infections. An oversubscribed Series F financing will support its lead candidate through a Phase II trial. Atox Bio, which has operations in the US and Israel, develops immune modulators for patients with severe infections. The biotech was established at the Hebrew University of Jerusalem and Yissum. […] December 4, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2017 Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III Idorsia will collaborate with Janssen on the development of its hypertension drug, aprocitentan, which could help to prevent future heart attacks and strokes. Idorsia was born out of Actelion’s massive $30B (€27.9B) acquisition by Johnson & Johnson, retaining all of the former biotech’s early-stage assets. The company develops small molecules for a broad range of […] December 4, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2017 Novozymes and Danish Pump Producer Set Sail in Pursuit of Clean Water As part of the company’s HelloScience initiative, Novozymes will combine its enzyme and microbial technology with Grundfos’ water pumps to provide clean water and better sanitation. Novozymes aims to improve industrial performance without harming our planet. Earlier this year, the company set up HelloScience, an online platform bringing together experts in a number of fields […] December 4, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 4 Dec 2017 Meet the CEO Leading Italy’s Charge to Become a Major Biotech Player Riccardo Palmisano is CEO of MolMed, the most important Italian biotech, which focuses on gene and cell therapies. We chatted about the company, which hopes to give the cancer therapies field a boost. You may have come across MolMed before, possibly in our recent piece on the top biotechs in Milan. The company was founded […] December 4, 2017 - 7 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2017 The Door Opens for Dutch Brain Surgery Device to Enter the Clinic Polyganics has received €1.2M to complete the development of its dura sealant patch, which will be used to reduce the complications of brain surgery. Polyganics, based in the Groningen Medtech Hub, develops bioresorbable medical devices that aid tissue repair and regeneration. Today, the company has announced that it has received €1.2M from the European Fund for Regional […] December 1, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 30 Nov 2017 Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib A Phase Ib trial will assess the capacity of Symphogen’s antibody to direct an antibiotic to Staphylococcus infections for their effective treatment. Symphogen focuses on the development of antibodies for the treatment of cancer, but will receive a $5M (€4.2M) milestone payment from Genentech for the use of one of its antibodies against Staphylococcus aureus infections. It […] November 30, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2017 Qiagen Joins French Biotech to Build the Next Generation of Microbiome Technology Biomillenia harnesses the power of bacteria to keep the body healthy. The biotech has joined forces with Qiagen to develop microbiome-on-a-chip technology. Scientists around the world believe that the microbiome could hold the key to human health. One company in this area, Biomillenia, develops microbial strains from previously unculturable microbiomes to unlock its full potential. The company has now […] November 30, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2017 What Exactly Happens in the Cells of People with Down’s Syndrome? Researchers in Switzerland have taken a closer look at the cells of Down’s syndrome patients, with widespread changes in protein expression observed. Down’s syndrome, or trisomy 21, is the most common genetic disease, characterized by facial dysmorphism, learning disabilities, poor muscle tone and heart problems. Research carried out at the University of Geneva and ETH […] November 29, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2017 Guilt-free and Odour-free: French Biotech Fights for Green Cosmetics Global Bioenergies has produced the first batch of its sustainable isobutene, which L’Oréal will use to produce environmentally friendly hairspray and deodorant. Global Bioenergies has produced the first batch of its sustainable biochemical for L’Oréal. The French biotech hopes to support the shift away from fossil fuels that could change the world. It has taken its first step […] November 29, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2017 Cheap DNA Tests for Everyone! Italian Biotech Launches €149 Kit Dante Labs has developed the first DNA tests available in Europe, which will allow the public to test their health and wellbeing from the comfort of their own homes. Dante Labs hopes to transform genetics. The biotech wants to develop accessible genomic testing, giving people the knowledge and information they need to live long, healthy lives. Yesterday, the […] November 28, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2017 The Link Between Type 2 Diabetes and Obesity may have Finally been Uncovered Researchers at the Université de Genève have unravelled the cellular and molecular mechanisms linking obesity and insulin resistance. We have long known about a link between obesity and type 2 diabetes, but discovering the underlying mechanisms has proved difficult. A group of researchers at the Université de Genève, Switzerland, may have found a protein that links changes […] November 28, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2017 Dutch Cancer Nanoparticles Get €2.5M from the EU to Enter Phase II The EU has awarded Cristal Therapeutics a grant from its Horizon 2020 program. This will support the development of its cancer nanoparticles through Phase II. Horizon 2020 is the biggest EU Research and Innovation program with close to €80B already handed out to help exciting science towards the market. Cristal Therapeutics is a biopharmaceutical company developing targeted nanomedicines for cancer and […] November 28, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email